Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Anti-von Willebrand Factor Nanobody, Caplacizumab
(Cablivi (TN))		[2] Caplacizumab (Cablivi),
Von Willebrand factor human		[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
2Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
(Cablivi (TN))		[2] Caplacizumab (Cablivi),
Von Willebrand factor human		[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
3CABLIVI[1] Caplacizumab (Cablivi)[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
4Cablivi®[1] Caplacizumab (Cablivi)[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
5CAPLACIZUMAB
(Cablivi (TN))		[1] Caplacizumab (Cablivi)[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
6Caplacizumab (ALX-0081)
(Cablivi (TN))		[1] Caplacizumab (Cablivi)[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
7Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
(Cablivi (TN))		[2] Caplacizumab (Cablivi),
Von Willebrand factor human		[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
8Caplacizumab (an anti-von Willebrand Factor Nanobody)
(Cablivi (TN))		[2] Caplacizumab (Cablivi),
Von Willebrand factor human		[1] Caplacizumab (Cablivi (TN)) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬